Chinese biopharmaceutical company Jiangsu Hengrui Medicine Co Ltd (SSE: 600276) and US biotech Arcutis Inc have entered into an exclusive option and licence agreement for the development and commercialisation of topical applications of Hengrui's investigational drug, SHR0302, for the treatment of dermatology disorders, the two companies announced on Friday.
SHR0302 is a highly potent, selective JAK inhibitor. It is currently in Phase 2 clinical trials for rheumatoid arthritis in China.
"Arcutis has been formed around a team of industry veteran leaders with deep expertise and an admirable track record in developing and commercialising dermatology therapeutics," said Lianshan Zhang, president of global R&D at Hengrui.
"There is high unmet need for a topical therapy with new mechanism of action to effectively address immune-mediated dermatology disorders. We are very excited to be a partner of Arcutis."
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial
Biosenic finalises agreement with Phebra for oral arsenic troxide development
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Allorion Therapeutics signs exclusive option and global license agreement with AstraZeneca